BRCA1 and BRCA2 Mutations: — How PARP Inhibitors Target Them

Not necessarily. BRCA mutations fall into two types. A germline mutation is inherited — it was present in every cell from birth and could have been passed down through the family. A somatic mutation developed in the tumour itself and is not inherited. Your oncologist or a genetic counsellor can confirm which type you have from your test report. If the mutation is germline, first-degree relatives — parents, siblings and children — may want to consider testing for themselves.

Only if the mutation is germline, meaning it was inherited rather than acquired by the tumour. A germline BRCA mutation can be passed on to children, and a genetic counsellor will explain the likelihood and what testing options exist for relatives. A somatic mutation found only in the tumour does not affect your children's inherited risk. Before speaking to family members, ask your oncologist or a genetic counsellor to confirm which type of mutation your test found, so you are giving them accurate information.

The most commonly reported side effects are nausea, fatigue and low blood counts — particularly anaemia and low platelets. Nausea often improves after the first few weeks and can be helped by timing your dose around meals. Anaemia is monitored through regular blood tests and sometimes needs a dose adjustment. Less commonly, some patients develop a condition affecting the bone marrow called myelodysplastic syndrome — this is one of the reasons your monitoring blood tests matter. Report any unusual bruising, breathlessness, or persistent worsening fatigue to your oncology team without waiting for your next scheduled appointment.

Resistance can develop over time, sometimes because the cancer acquires a secondary mutation that partially restores the DNA repair pathway. Your oncologist monitors your response through imaging and, where relevant, tumour markers. If the cancer progresses on a PARP inhibitor, there are further treatment lines to consider — chemotherapy, other targeted agents, or clinical trials where eligible. We do not yet fully understand all the mechanisms of resistance, and this remains an active area of research. Reporting any new symptoms early gives your team the most options.

PARP inhibitors are among the more expensive oral cancer medicines. Any cost figure you see online is indicative and changes with exchange rates, import duties and generic availability in India — treat any number as a starting point only. Patient assistance programmes exist for some agents through manufacturers, and your oncologist's team can advise on what is currently accessible. Ayushman Bharat and some state government schemes cover certain oncology medicines — ask your hospital's billing team whether your specific treatment qualifies before assuming you will bear the full cost.

Some combinations are included in current NCCN and ESMO guidelines for specific situations — for example, combining a PARP inhibitor with an anti-angiogenic agent in certain ovarian cancer settings. Whether a combination applies to your case depends on your cancer type, stage and treatment history. Do not add any medicines, supplements or herbal preparations without telling your oncology team first. Some substances affect how PARP inhibitors are broken down by the body, which can alter their effect or increase side effects.